Okayama University

LANGUAGE
JAPANESECHINESE
MENU

Okayama University Medical Research Updates (OU-MRU) Vol.73

December 10, 2019

Source: Okayama University (JAPAN), Public Relations Division
For immediate release: 4 December 2019
Okayama University research: Primary intraocular lymphoma does not always spread to the central nervous system

(Okayama, 4 December) Researchers at Okayama University report in the Journal of clinical and experimental hematopathology that primary intraocular lymphoma, a cancer in the eye, does not always develop into central nervous system lymphoma. In addition, the scientists confirmed that there is no marker available to predict when the former will develop into the latter.

Primary intraocular lymphoma (PIOL) is a cancer in the eye originating in lymphocytes, cells of the immune system that fight infections; lymphoma is the condition when lymphocytes grow in an uncontrolled way. Often, PIOL develops into central nervous system lymphoma — uncontrolled growth of lymphocytes in the nervous system in the brain and the spinal cord. It is not clear, however, whether this development always occurs. Now, Professor MATSUO Toshihiko (eye doctor) and Assistant Professor TANAKA Takehiro (pathologist) from Okayama University have addressed the question whether there are PIOLs that do not develop central nervous system lymphoma. They observed a group of patients, and found that in the small number of cases, PIOL does not spread to the central nervous system. Importantly, PIOL has a good prognosis if it does not develop into central nervous system lymphoma.

The researchers studied 22 patients (14 women, 8 men) for up to 14 years. The patients’ ages ranged from 42 to 84 years at the time of the first eye examination. In 12 patients, both eyes were affected by PIOL; in the others, only one eye. All 22 patients underwent vitrectomy (surgery in which some or all of the vitreous gel between the retina and the lens in the middle of the eye is removed) after diagnosis of PIOL.

Of the 22 patients, 17 developed central nervous lymphoma. For 3 of the 5 patients who did not, the follow-up period was relatively short (up to 3 years). The follow-up periods for the other 2 patients were 5 and 11 years; these patients did not undergo chemotherapy or radiation of the eye. Based on these long-term follow-up results, Matsuo and Tanaka concluded that PIOL does not necessarily develop into central nervous system lymphoma.

The scientists also examined whether the presence of a protein called CD5 in specimens taken during vitrectomy surgery are a marker of central nervous system lymphoma. But both patients with CD5-positive and patients with CD5-negative tests developed central nervous system lymphoma, which made Matsuo and Tanaka conclude that “at present, there is no marker available to predict whether a patient with PIOL will develop central nervous system lymphoma.”

Background
Primary intraocular lymphoma (PIOL)

Primary intraocular lymphoma (PIOL) is a cancer that involves the retina, the vitreous chamber in the middle of the eye and/or the optic nerve. It manifests itself as opacity of the gel in the vitreous chamber, which can be accompanied by lesions in the retina, in subretinal pigment epithelium (beneath the pigmented cell layer just outside the retina), or in the optic nerve. Often, PIOL develops into central nervous system lymphoma, simultaneously or at a later time. Professor MATSUO Toshihiko and Assistant Professor TANAKA Takehiro from Okayama University have now investigated if PIOL also occurs without development into central nervous system lymphoma, and whether a marker for such development exists.

Reference
Toshihiko Matsuo, Takehiro Tanaka. Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?. Journal of Clinical and Experimental Hematopathology, Vol. 59 No.4, 2019.
DOI : https://doi.org/10.3960/jslrt.19019
https://www.jstage.jst.go.jp/article/jslrt/advpub/0/advpub_19019/_article/-char/ja/


Reference (Okayama Univ. e-Bulletin): Professor MATSUO’s team
e-Bulletin Vol.8:Photoelectric dye-coupled thin film as a novel type of retinal prosthesis
OU-MRU Vol.8:Light-responsive dye stimulates sight in genetically blind patients
OU-MRU Vol.39:Successful test of retinal prosthesis implanted in rats
OU-MRU Vol.47:Candidate genes for eye misalignment identified
OU-MRU Vol.53:Successful implantation and testing of retinal prosthesis in monkey eyes with retinal degeneration
OU-MRU Vol.70:Prosthetics for Retinal Stimulation

Correspondence to
Professor MATSUO Toshihiko, M.D., Ph.D.
Ophthalmology, Okayama University Medical School and
Graduate School of Interdisciplinary Science and Engineering
in Health Systems,
2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
E-mail: matsuot(a)cc.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.

Website: //www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
We love OKAYAMA UNIVERSITY: https://www.youtube.com/watch?v=7cXlttQIk3E
Okayama University Image Movie(2018)
https://www.youtube.com/watch?v=WmyqOTuigBs

Okayama University Medical Research Updates (OU-MRU)
The whole volume : OU-MRU (1- )
Vol.1:Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
Vol.2:Ensuring a cool recovery from cardiac arrest
Vol.3:Organ regeneration research leaps forward
Vol.4:Cardiac mechanosensitive integrator
Vol.5:Cell injections get to the heart of congenital defects
Vol.6:Fourth key molecule identified in bone development
Vol.7:Anticancer virus solution provides an alternative to surgery
Vol.8:Light-responsive dye stimulates sight in genetically blind patients
Vol.9:Diabetes drug helps towards immunity against cancer
Vol.10:Enzyme-inhibitors treat drug-resistant epilepsy
Vol.11:Compound-protein combination shows promise for arthritis treatment
Vol.12:Molecular features of the circadian clock system in fruit flies
Vol.13:Peptide directs artificial tissue growth
Vol.14:Simplified boron compound may treat brain tumours
Vol.15:Metamaterial absorbers for infrared inspection technologies
Vol.16:Epigenetics research traces how crickets restore lost limbs
Vol.17:Cell research shows pathway for suppressing hepatitis B virus
Vol.18:Therapeutic protein targets liver disease
Vol.19:Study links signalling protein to osteoarthritis
Vol.20:Lack of enzyme promotes fatty liver disease in thin patients
Vol.21:Combined gene transduction and light therapy targets gastric cancer
Vol.22:Medical supportive device for hemodialysis catheter puncture
Vol.23:Development of low cost oral inactivated vaccines for dysentery
Vol.24:Sticky molecules to tackle obesity and diabetes
Vol.25:Self-administered aroma foot massage may reduce symptoms of anxiety
Vol.26:Protein for preventing heart failure
Vol.27:Keeping cells in shape to fight sepsis
Vol.28:Viral-based therapy for bone cancer
Vol.29:Photoreactive compound allows protein synthesis control with light
Vol.30:Cancer stem cells’ role in tumor growth revealed
Vol.31:Prevention of RNA virus replication
Vol.32:Enzyme target for slowing bladder cancer invasion
Vol.33:Attacking tumors from the inside
Vol.34:Novel mouse model for studying pancreatic cancer
Vol.35:Potential cause of Lafora disease revealed
Vol.36:Overloading of protein localization triggers cellular defects
Vol.37:Protein dosage compensation mechanism unravelled
Vol.38:Bioengineered tooth restoration in a large mammal
Vol.39:Successful test of retinal prosthesis implanted in rats
Vol.40:Antibodies prolong seizure latency in epileptic mice
Vol.41:Inorganic biomaterials for soft-tissue adhesion
Vol.42:Potential drug for treating chronic pain with few side effects
Vol.43:Potential origin of cancer-associated cells revealed
Vol.44:Protection from plant extracts
Vol.45:Link between biological-clock disturbance and brain dysfunction uncovered
Vol.46:New method for suppressing lung cancer oncogene
Vol.47:Candidate genes for eye misalignment identified
Vol.48:Nanotechnology-based approach to cancer virotherapy
Vol.49:Cell membrane as material for bone formation
Vol.50:Iron removal as a potential cancer therapy
Vol.51:Potential of 3D nanoenvironments for experimental cancer
Vol.52:A protein found on the surface of cells plays an integral role in tumor growth and sustenance
Vol.53:Successful implantation and testing of retinal prosthesis in monkey eyes with retinal degeneration
Vol.54:Measuring ion concentration in solutions for clinical and environmental research
Vol.55:Diabetic kidney disease: new biomarkers improve the prediction of the renal prognosis
Vol.56:New device for assisting accurate hemodialysis catheter placement
Vol.57:Possible link between excess chewing muscle activity and dental disease
Vol.58:Insights into mechanisms governing the resistance to the anti-cancer medication cetuximab
Vol.59:Role of commensal flora in periodontal immune response investigated
Vol.60:Role of commensal microbiota in bone remodeling
Vol.61:Mechanical stress affects normal bone development
Vol.62:3D tissue model offers insights into treating pancreatic cancer
Vol.63:Promising biomarker for vascular disease relapse revealed
Vol.64:Inflammation in the brain enhances the side-effects of hypnotic medication
Vol.65:Game changer: How do bacteria play Tag ?
Vol.66:Is too much protein a bad thing?
Vol.67:Technology to rapidly detect cancer markers for cancer diagnosis
Vol.68:Improving the diagnosis of pancreatic cancer
Vol.69:Early gastric cancer endoscopic diagnosis system using artificial intelligence
Vol.70:Prosthetics for Retinal Stimulation
Vol.71:The nervous system can contribute to breast cancer progression
Vol.72:Synthetic compound provides fast screening for potential drugs

ACADEMIC YEAR